ACC.17 - PACE-CME

Episodes 17-19 of 19

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time
Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time
ACC.17
Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time
PCSK9 inhibitors: From bench to bedside
PCSK9 inhibitors: From bench to bedside
ACC.17
PCSK9 inhibitors: From bench to bedside
- Prof. Gilles Lambert
CV outcomes with a PCSK9 inhibitor: FOURIER study
CV outcomes with a PCSK9 inhibitor: FOURIER study
ACC.17
CV outcomes with a PCSK9 inhibitor: FOURIER study

Previous
1
2
Next

2/2